GSK, Impax terminate IPX066 development deal
The termination is attributed to delay in the expected regulatory approval and launch dates in countries where GSK holds commercialization rights. According to the terms of the deal
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
According to the deal, Merck, through a subsidiary, and Pfizer will work on the development and marketing of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin)